MAMasab Ali

Masab Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masab Ali has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Frequency of Metabolic Syndrome in Patients With Hepatitis C Virus Infection: A Cross‐Sectional Study

    by Muhammad Awais, Maryam Ilyas, Muhammad Husnain Ahmad, Muhammad Taha Shaukat, Abdul Waheed, Aniqa Iqbal, Muhammad Umar Nadeem, Nimra Mahmood, Ali Gohar, Hamza Zaheer, et al.

    Background and Aim: Metabolic syndrome significantly increases the risk of cardiovascular disease and type 2 diabetes. Hepatitis C virus (HCV) infection has been associated with an increased risk of metabolic syndrome. This study aims to explore this association to improve management strategies for HCV patients at risk of metabolic syndrome. Methods: A cross‐sectional observational study was conducted in the Department of Medicine, Lahore General Hospital, Lahore, from December 3, 2022, to June 2, 2023. The study employed non‐probability consecutive sampling to include 115 patients diagnosed with HCV infection for at least 6 months. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria for Asian‐Americans. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) version 26.0. Results: Out of 115 individuals with HCV infection, 36 (31.3%) were found to have metabolic syndrome. The condition was slightly more prevalent among males (33.3%) than females (29.3%), although this difference was not statistically significant ( p = 0.642). A higher frequency of metabolic syndrome was observed in participants aged 31–45 years (34.8%) and 46–60 years (32.0%) compared to those aged 15–30 years (21.1%), but this variation was also not significant ( p = 0.549). The duration of HCV infection showed no significant relationship with the presence of metabolic syndrome ( p = 0.386). Multivariable logistic regression further confirmed that gender, age group, and duration of infection were not independently associated with metabolic syndrome. Conclusions: This study indicates that while metabolic syndrome is fairly common among individuals with HCV infection and in older age, its occurrence does not show a significant association with gender, age, or the duration of infection. These results underscore the need for further studies to clarify the complex interplay between HCV and metabolic disturbances.

  • Open Access

    Trends and Demographic Disparities Among Adults With Sudden Cardiac Death and Diabetes Mellitus in the United States: A Nationwide Analysis

    by Taha Mehmood, Muhammad Abdullah, Masab Ali, Amina Jamil, Muhammad Husnain Ahmad, Muhammad Mujtaba Tariq, Areej Asif, Sunnia Khan, Moeez Ahmad Saeed, Muhammad Hassan, et al.

    Background: Sudden cardiac death (SCD) represents a major cause of cardiovascular mortality, with diabetes mellitus (DM) significantly increasing susceptibility. However, long‐term national trends and demographic disparities in SCD among decedents with co‐documented SCD and DM remain insufficiently characterized. Methods: We conducted a retrospective analysis using the CDC WONDER database from 1999 to 2020. Adults with SCD and DM listed on death certificates were included. Age‐adjusted mortality rates (AAMRs) per 100 000 population were calculated and stratified by sex, age group, race/ethnicity, census region, state, and urbanization status. Temporal trends were assessed using annual percent changes (APCs), with p < 0.05 considered statistically significant. Results: A total of 51 756 deaths among decedents with co‐documented SCD and DM were identified. Overall AAMR increased from 1.29 in 1999 to 1.46 in 2020 (APC +0.46%, p = 0.012). Men had significantly higher mortality than women. Older adults (≥ 75 years) exhibited the highest mortality burden, though relative increases were notable in younger groups. Black individuals had the highest mortality, with a sharp rise in 2020. Rural populations experienced higher mortality than urban counterparts, with significant upward trends. Southern states demonstrated the highest regional burden. Conclusion: The population‐level burden of co‐documented SCD and DM in the United States has increased modestly over the past two decades, with significant demographic and geographic disparities. Targeted public health interventions and equitable cardiovascular risk management are urgently needed to reduce these disparities.

  • Open Access

    Mortality among U.S. adults with coexisting type 2 diabetes mellitus and malignant neoplasms: A nationwide observational study (1999–2024)

    by Muhammad Husnain Ahmad, Masab Ali, Muhammad Hassan, Muhammad Abdullah, Moiz Ul Haq Hashmi, Amina Jamil, Taha Mehmood, Abdullah Zaheer, Ahmad Zia, Muhammad Umar Shahid, et al.

    Type 2 diabetes mellitus (T2DM) and malignant neoplasms are among the most prevalent chronic diseases worldwide. When coexisting, they substantially increase morbidity and mortality. However, national trends in mortality among patients with coexisting T2DM and malignant neoplasms in the United States remain underexplored. We analyzed U.S. death certificates from the CDC WONDER database for individuals aged ≥ 25 years who died between 1999 and 2024 with both T2DM and malignant neoplasms listed anywhere on the death certificate (underlying or contributing causes). Age-adjusted mortality rates (AAMRs) and annual percent change (APC) were calculated by year, sex, age group, race/ethnicity, geographic region, and urbanization status. From 1999 to 2024, 357,910 U.S. deaths occurred among individuals in whom both Type 2 Diabetes Mellitus and Malignant Neoplasms were listed on the death certificate. The AAMR rose from 6.37 to 17.2 per 100,000, with an overall APC of + 3.84%. Men exhibited higher mortality than women. Older adults bore the greatest burden, though middle-aged adults also showed a sharp proportional rise. Hispanic and Asian populations experienced the steepest increases. The West region showed the most pronounced growth. State-level variation exceeded fivefold, with Nebraska reporting the highest AAMR and Nevada the lowest. nonmetropolitan areas maintained higher mortality throughout, but metropolitan areas demonstrated a steeper rise, narrowing the rural–urban gap. Mortality among individuals with coexisting T2DM and malignant neoplasms has risen substantially in the U.S., with disproportionate increases among men, minority populations, and urban residents. These findings highlight the urgent need for integrated strategies addressing diabetes control, cancer prevention, and health equity across demographic and geographic subgroups.

  • Open Access

    Overlap of Primary Biliary Cholangitis and Systemic Sclerosis: A Case of Reynolds Syndrome

    by Ali Gohar, Ira Abid, Syeda Eman Fatima, Abdum Muneeb Sandhu, Zain Fatima, Humayun Nasir, Fatima Arshad, Abdul Rehman Shahid Khan, Muhammad Husnain Ahmad, Masab Ali

    Reynolds Syndrome should be suspected in CREST patients with persistent cholestatic liver enzymes, since delayed diagnosis allows portal hypertension and variceal bleeding to develop. Early anti‐mitochondrial antibody screening and prompt ursodeoxycholic acid therapy improve outcomes, and these patients need multidisciplinary follow‐up for lung and thyroid disease.

  • Open Access

    Trends in urinary tract infection–related mortality among older adults with dementia in the United States: A population-based observational study using CDC WONDER (1999–2020)

    by Aasim Mbbs Ali, Masab Mbbs Ali, Muhammad Mbbs Abdullah, Muhammad Mbbs Hassan, Taha Mbbs Mehmood, Muhammad Husnain Mbbs Ahmad, Waqar Ahmed Mbbs Cheema, Muhammad Mujtaba Mbbs Tariq, Ahmad Mbbs Zia, Muhammad Mbbs Asadullah, et al.

    Dementia is a major cause of morbidity and mortality among older adults, and urinary tract infections (UTIs) are frequent, clinically significant complications in this population. However, there is limited national evidence describing mortality trends where UTI is listed as the underlying cause of death among individuals with dementia in the United States. We conducted a population-based descriptive study using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research Multiple Cause-of-Death database (1999–2020). Deaths were identified using International Classification of Diseases, 10th Revision codes for UTI (N39.0) as the underlying cause and unspecified dementia (F03) as a multiple cause. We computed crude and age-adjusted mortality rates (AAMR) per 100,000, standardized to the 2000 US population. Temporal trends were assessed using joinpoint regression to estimate annual percent change and 95% confidence intervals (CIs), stratified by sex, age, race/ethnicity, region, and urbanization. Between 1999 and 2020, 125,797 deaths were attributed to UTI with comorbid unspecified dementia. The national AAMR increased from 18.20 to 26.30 per 100,000, with a non-significant annual percent change (−0.44%, 95% confidence interval = −1.38 to 0.51), suggesting no consistent annual increase. Mortality increased similarly in both sexes, but the absolute burden was higher in women. The highest mortality occurred among adults aged ≥75 years. Non-Hispanic White individuals accounted for most deaths and showed a 51.1% increase in AAMR. The greatest state-level rates were observed in South Carolina, North Carolina, West Virginia, Oklahoma, and Tennessee, while the lowest were in Arizona, Nevada, and Hawaii. Nonmetropolitan areas consistently experienced higher mortality. Mortality due to UTI as the underlying cause of death among older adults with dementia remained stable in the United States from 1999 to 2020, with notable geographic and demographic disparities. Women, non-Hispanic Whites, older adults, and rural residents carried the highest burden. These findings highlight the urgent need for improved infection prevention, timely diagnosis of atypical UTI presentations, and equitable access to healthcare for dementia patients, particularly in high-risk and rural regions.

  • Open Access

    Trends in nontraumatic intestinal perforation-related mortality among adults in the United States from 1999 to 2020: A nationwide CDC WONDER analysis

    by Onyekachi Emmanuel Anyagwa, Hashim Mohamed Siraj, Hanzala Zahid, Oluwatoyin Adalia Dairo, Muhammad Husnain Ahmad, Muskan Joshi, Mohammad Aamir Qayyum Sarguroh Khan, Anas Abdulkader, Masab Ali, Abhirami Babu, et al.

    To characterize mortality trends associated with nontraumatic intestinal perforation (NIP) in the United States, which continue to remain poorly defined. NIP is defined as the loss of continuity of the bowel wall in which external trauma as an etiology has been excluded. NIP is a serious gastrointestinal emergency with limited national mortality trend data, particularly across various demographic and regional subgroups. NIP-related mortality data were extracted from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database from 1999 to 2020. We analyzed age-adjusted mortality rates (AAMR) per 100,000 individuals and annual percent change (APCs) with 95% confidence interval (CI) in patients ≥ 15 years based on gender, race and geographical region. Overall, there were 122,161 NIP-related deaths among patients aged ≥ 15 years, with an increase in AAMR from 1.90 in 1999 to 2.0 in 2009 (APC: 0.19; CI: −0.33 to 0.71), and a gradual increase to 2.40 in 2020 (APC: 1.26; CI: 0.80 to 1.71). AAMR was lower in females compared to males in 1999 (2.0 vs 1.90; CI: 1.90 to 2.0). However, in 2020, AAMR values increased in females (2.20 vs 2.0; CI: 2.40 to 2.60; P < .05). AAMRs were higher in patients reported as non-Hispanic compared to Hispanic/Latinos (2.10 vs 1.50; CI: 2.10 to 2.10; P < .05). Variation in AAMR values across census regions was not significant. NIP-related AAMR was higher in nonmetropolitan than metropolitan areas (2.90 vs 1.90; CI: 2.10 to 2.10; P < .05). NIP-related mortality has risen among patients’ ≥15 years. Higher AAMRs in females, non-Hispanic individuals, and nonmetropolitan populations highlight the need for targeted preventive efforts.

  • Open Access

    Surgical Management of Arterial Thoracic Outlet Syndrome due to Cervical Rib in a 17‐Year‐Old Male With Gangrenous Ulcer on Fingertip Requiring Multiple Bypass: A Case Report

    by Ilsa Babar, Sunaina Tariq, Ali Haider Ehsan Khan, Muhammad Husnain Ahmad, Masab Ali, Ayisha Maqsood, Zaid Ashraf Mirza

    Arterial thoracic outlet syndrome (ATOS) is a rare condition, affecting 1% to 5% of TOS cases, characterized by the compression of the subclavian artery, often due to anatomical anomalies like cervical ribs. Cervical ribs that are not a very common anatomical anomaly can give rise to arterial supply compromise needing surgical intervention to undo the compression is the highlight of this case report. A 17‐year‐old male presented with progressive numbness, pain, and a gangrenous ulcer on his right index finger, aggravated by exertion. Clinical examination revealed absent pulses in the right hand, with intact motor and sensory functions. Doppler ultrasound confirmed thrombosis extending from the brachial artery into the radial and ulnar arteries. A neck radiograph and CT angiogram revealed a cervical rib compressing the subclavian artery, leading to aneurysm formation. The patient was diagnosed with ATOS complicated by arterial thrombosis. Surgical intervention was performed, including right cervical rib excision, resection of the scalenus anterior muscle, and bypass procedures to restore blood flow. Thrombectomy was performed on the brachial, radial, and ulnar arteries. The postoperative course was uneventful, with restored pulses and improved circulation. Follow‐up Doppler ultrasounds confirmed patent grafts and resolution of ischemic symptoms. This case highlights the importance of early recognition and surgical management of ATOS, particularly in young patients with anatomical variations like cervical ribs. Surgical decompression and revascularization can lead to significant improvement in symptoms and vascular perfusion. Regular follow‐up is essential to monitor graft patency and prevent recurrence. Our case study is unique from previous studies as it presents a complicated case of ATOS with multiple thromboses in the brachial, radial, and ulnar arteries and an extensive treatment plan including surgical resection of cervical rib and scalenus muscle; furthermore, thrombectomy and brachio radial bypass to restore distal blood flow.

  • Open Access

    Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non‐Diabetic Adults: A Narrative Review

    by Ayesha Laraib, Uswa Ahmad, Syeda Iman Laraib, Syeda Wardah Laraib, Masab Ali, Muhammad Husnain Ahmad, Muhammad Hassan

    Background and Aims: The rising global prevalence of obesity has catalyzed the development of potent glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable semaglutide for weight management, specifically in non‐diabetic adults, a population where weight loss outcomes often differ from those seen in diabetic cohorts. Methods: Using information from PubMed, Scopus, and Web of Science, a thematic synthesis was carried out under the guidance of the SANRA procedural framework (2019–2025). The search used tirzepatide as a comparative benchmark and a particular Boolean string to target semaglutide efficacy in non‐diabetic groups. To evaluate metabolic effects and practical obstacles, data from 27 studies including observational studies, randomized controlled trials (RCTs), and qualitative reports, were analytically combined. Results: In adults without diabetes, semaglutide (2.4 mg) shows better weight loss efficacy, with mean reductions of roughly 14.9% as opposed to 9.6% in diabetic groups. Significant improvements in cardiometabolic indicators and quality‐of‐life assessments were observed in addition to weight loss. Nevertheless, the main reason for stopping is still gastrointestinal side effects. Long‐term therapeutic utility is greatly impacted by practical obstacles, such as high out‐of‐pocket expenses, worldwide supply limitations, and the possibility of weight gain after cessation. Conclusion: Although semaglutide is a novel obesity disease‐modifying medication, its effectiveness depends on how well it is incorporated into multimodal treatment plans. Even though its effectiveness has been shown, equitable public health implementation requires addressing structural issues and safety concerns, such as drug pricing models and insurance coverage. Long‐term durability studies and head‐to‐head trials with next‐generation incretins should be the top priorities for future research.


  • Open Access

    May–Thurner Syndrome: An Under‐Recognized Etiology of Deep Vein Thrombosis (DVT)

    by Abdul Rehman Shahid Khan, Yashika Gupta, Betsy Samuel, Yeshwini Murali Krishna, Muhammad Husnain Ahmad, Haseeb Ahmad, Iqra Nasir, Masab Ali, Danish Ali Chohan, Muhammad Umar Nadeem, et al.

    Background and Aims: May–Thurner Syndrome (MTS) is a rare vascular condition characterized by the compression of the left iliac vein by the overlying right iliac artery. This anatomical anomaly predisposes patients, especially young to middle‐aged women, to deep vein thrombosis (DVT), which when it persists, leads to complications such as pulmonary embolism and chronic venous insufficiency. Despite its clinical significance, there is a lack of standardized guidelines for diagnosis and management. This review aims to summarize current knowledge on the epidemiology, pathophysiology, diagnostic approaches, and therapeutic strategies for MTS while highlighting challenges in establishing a consistent clinical framework. Methods: A comprehensive literature search was conducted using PubMed and Google Scholar, focusing on English‐language studies involving human subjects. Sources included case reports, case series, clinical trials, systematic reviews, and expert consensus guidelines. Additional literature on iliac vein pathophysiology and venous thromboembolism management was reviewed to provide broader clinical context. Reference lists of key publications were manually examined for additional relevant studies. The final literature search was completed on April 5, 2025. Results: Common diagnostic methods for MTS include duplex ultrasound, CT venography, and MR venography, with intravascular ultrasound showing the highest sensitivity (> 98%). Endovascular stenting, often combined with catheter‐directed thrombolysis, provides significant symptom relief and reduces post‐thrombotic syndrome. In contrast, angioplasty alone was linked to higher recurrence rates. Long‐term patency rates following stenting ranged from 79% to 100%. However, the absence of standardized diagnostic and treatment protocols contributes to variability in clinical outcomes. Conclusion: MTS remains an underrecognized cause of DVT, especially among young women. Although advances in diagnostic imaging and minimally invasive interventions have improved management, the lack of evidence‐based guidelines continues to interfere with optimal care. Early diagnosis and individualized treatment plans are crucial, and further research is needed to establish evidence‐based protocols for consistent management of MTS.

  • Open Access

    Emerging trends and disparities in mortality due to coexisting atrial fibrillation and sepsis: A US nationwide observational study (1999–2023)

    by Masab Mbbs Ali, Rehan Mbbs Naseer Ahmad, Muhammad Mbbs Hassan, Moiz Ul Haq Mbbs Hashmi, Madiha Kiyani, Ahmad Mbbs Zia, Jawaria Mbbs Firdous, Muhammad Husnain Mbbs Ahmad, Ali Mbbs Imran, Amina Mbbs Jamil, et al.

    Sepsis patients are highly susceptible to atrial fibrillation (AF) and atrial flutter due to the proinflammatory and adrenergic milieu, which precipitates arrhythmogenesis, especially in vulnerable individuals. Understanding mortality trends and disparities in this population is essential for targeted interventions. We analyzed US death certificates from the Center of Disease Control Wide-Ranging Online Data for Epidemiologic Research database for individuals aged ≥25 years who died between 1999 and 2023 with both sepsis and AF listed as causes. We calculated age-adjusted mortality rates (AAMRs), which measure changes in death rates over time while accounting for differences in age distribution, and annual percent change to evaluate yearly trends in these rates across demographic groups stratified by year, sex, age group, race/ethnicity, geographic region, and urbanization status. A total of 2,40,222 deaths involved both AF/atrial flutter and sepsis. The overall AAMR increased from 2.0 per 1,00,000 in 1999 to a peak of 7.9 in 2021 (annual percent change +5.6% through 2018, accelerating to +12.6% through 2021), with a slight decline to 7.1 by 2023. Mortality was consistently higher in men than women, older adults, residents of nonmetropolitan areas, and the US South. By race/ethnicity, non-Hispanic White and Black individuals had the highest AAMRs, followed by American Indian/Alaska Native, Hispanic, and Asian/Pacific Islander populations. Deaths involving AF and sepsis have risen substantially over the past 4 decades, with sharp increases in recent years and persistent disparities by age, sex, race/ethnicity, and geography. These findings underscore the need for integrated arrhythmia–sepsis management strategies, enhanced access to critical care in underserved regions, and equity-focused public health interventions to mitigate mortality.